Status:

ACTIVE_NOT_RECRUITING

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Lead Sponsor:

Centre Oscar Lambret

Collaborating Sponsors:

Canceropôle Nord Ouest

Conditions:

Liver Cancer

Liver Metastases

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to ...

Detailed Description

Patients will first go through an inclusion check-up consisting of: * a clinical exam: disease history, previous treatments, weight, height, patient's performance status (ECOG) and HCC status. * a bi...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years old
  • With primary or secondary liver tumor and matching one of the following situations:
  • Liver Metastasis (LM): anatomopathologic diagnosis of the primary tumor
  • Hepatocellular Carcinoma (HCC): diagnosis achieved through biopsy or through non-invasive methods approved by AASLD criteria (Bruix, 2011)
  • Cholangiocarcinoma (CC): diagnosis achieved through biopsy
  • Other primitive hepatic tumor achieved through biopsy
  • Meet the requirements for SBRT treatment:
  • Liver Metastasis (LM): oligometastatic disease
  • Hepatocellular Carcinoma (HCC): non eligible lesion to curative surgery
  • Cholangiocarcinoma (CC): nodular lesion
  • Other primitive hepatic tumor: non eligible lesion to curative surgery
  • Able to receive a SBRT treatment according to the multidisciplinary consultation meeting
  • Tumor assessable with CT-scan or MRI according to mRECIST in HCC or Recist 1.1 in other situations
  • Affiliation to the National Social Security System
  • With informed and signed consent

Exclusion

  • Eligibility to a curative surgery according to the multidisciplinary consultation meeting
  • Contraindication to SBRT (especially Cirrhose Child C)
  • Pregnant or breastfeeding women
  • Patient Under guardianship or tutorship
  • Impossibility to submit at the study procedures due to geographic, social or mental reasons

Key Trial Info

Start Date :

March 13 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2027

Estimated Enrollment :

280 Patients enrolled

Trial Details

Trial ID

NCT03408665

Start Date

March 13 2019

End Date

December 1 2027

Last Update

February 13 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Centre Oscar Lambret

Lille, Nord, France, 59020

2

Centre Léonard de Vinci

Dechy, France

3

Institut Régional du Cancer de Montpellier

Montpellier, France

4

Institut de Cancérologie Paris Nord

Sarcelles, France, 95200